Company intelligence / Profile preview

Metavant Sciences

New York City, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Metavant Sciences has developed two investigational small-molecule drugs for metabolic disorders, especially diabetes. One marketed program was imeglimin, an oral anti-diabetic, but development rights for this asset reverted to Poxel in 2021, suggesting Metavant's pipeline shifted or reduced. No formal clinical results are published for current programs under Metavant; pipeline seems focused on diabetes and metabolic syndrome.

Therapeutic areas: EndocrinologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Partnerships

Previous partnership/licensing with Poxel for imeglimin, which ended January 2021

Beyond the preview

Go deeper on Metavant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Metavant Sciences.

Explore the full profile